CLL: experts discuss workup and treatment strategies

  • David Henry, MD; Anthony R. Mato, MD; Lindsey Roeker, MD
  • Medscape.com
  • 14 Apr 2020

  • curated by Pavankumar Kamat
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In an interview hosted by David Henry, MD, of Pennsylvania Hospital in Philadelphia, 2 hematologic oncologists — Anthony R. Mato, MD, and Lindsey Roeker, MD, both of Memorial Sloan Kettering Cancer Center in New York — discuss treatment tips in chronic lymphocytic leukemia (CLL).

Key points

  • Workup:
    • Initial workup of CLL must also include fluorescence in situ hybridization, looking for trisomy 12 as well as deletions in 13q, 17p, and 11q.
    • Next-generation sequencing to determine TP53 mutations and IgVH mutational analysis is also important.
    • Mutated IgVH disease tends to respond a bit better to therapy.
  • Choice of the first treatment:
    • If the disease is IgVH unmutated, chemoimmunotherapy combinations are not considered, regardless of patient age or fitness.
    • A novel agent as the first therapy is suitable.
      • The standard option is ibrutinib plus or minus obinutuzumab.
      • There is also an option of time-limited (1 year) venetoclax plus obinutuzumab.
      • The third option is recently approved acalabrutinib with or without obinutuzumab.
  • Advice for using venetoclax:
    • For a patient with a white blood cell (WBC) count of 100,000 µL being considered for oral venetoclax, it is advisable to start with 20 mg and then have an escalation every 7 days. 
    • Sometimes high-risk patients need to be in-house for 48 hours once a week for the first couple of weeks, until their WBC count falls.
    • Debulking with obinutuzumab clears out a lot of the WBCs and potentially "melts away" some of the nodes.
    • Evidence shows a 36-month PFS of ~82% with 1 year of venetoclax therapy.
    • Ibrutinib and acalabrutinib are treat-to-progression approaches that appeal to patients who are unwilling to come to the hospital or do not want to consider an infusional-based therapy. 
  • Treating relapse:
    • In a patient with relapse, IgVH status is not likely to change, but TP53 mutational status can change.
    • For TP53-mutated disease treated with venetoclax with relapse after 3 years, it would be ideal to retreat with the same regimen or to switch to a Bruton's tyrosine kinase (BTK) inhibitor.
    • Emerging data indicate response rates exceeding 80% for BTK inhibitors after venetoclax.
    • Dr. Mato expressed no concerns with the use of a rituximab biosimilar, although he had not used one yet.